Retracted: Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: A meta-analysis (Gastroenterology Research and Practice (2014) 2014:11 (827989) DOI: 10.1155/2014/827989);Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: A meta-analysis

Gastroenterology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Li, Qiang ^a   Liu, Ying ^b   Zhang, Hong Mei ^a   Huang, Yin Peng ^a   Wang, Tian Yi ^b   Li, Dong Sheng ^a   Sun, Hong Zhi ^a  

^a JINING NO 1 PEOPLE S HOSPITAL   (China)

^b Laiwu Municipal Center for Disease Control and Prevention   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHINESE BIOMEDICAL DATABASE; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; COLORECTAL CANCER; ETHNICITY; GENETIC POLYMORPHISM; HUMAN; MEDLINE; META ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WEB OF SCIENCE;

EID: 84921280613     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2020/9470819     Document Type: Erratum

References (23)

1. J. E. Meyer, T. Narang, F. H. Schnoll-Sussman, M. B. Pochapin, P. J. Christos, and D. L. Sherr, "Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database," Cancer, vol. 116, no. 18, pp. 4354-4359, 2010.
2. R. Siegel, D. Naishadham, and A. Jemal, "Cancer statistics, 2013," CA:ACancer Journal forClinicians, vol. 63, no. 1, pp. 11-30, 2013.
3. A. P. Stillwell, P. G. Buettner, and Y. H. Ho, "Meta-analysis of survival of patients with stage iv colorectal cancer managedwith surgical resection versus chemotherapy alone," World Journal of Surgery, vol. 34, no. 4, pp. 797-807, 2010.
4. M. Ducreux, A. Adenis, J.-P. Pignon et al. , "Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase ii study of bevacizumab plus 5- fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)," European Journal ofCancer, vol. 49, no. 6, pp. 1236-1245, 2013.
5. J. Li, N. Hou, A. Faried, S. Tsutsumi, and H. Kuwano, "Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model," European Journal of Cancer, vol. 46, no. 10, pp. 1900-1909, 2010.
6. R. Holma, R. Korpela, U. Sairanen et al. , "Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer," Journal of Clinical Gastroenterology, vol. 47, no. 1, pp. 45-51, 2013.
7. A. Di Paolo, M. Lencioni, F. Amatori et al. , "5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer," Clinical Cancer Research, vol. 14, no. 9, pp. 2749-2755, 2008.
8. M. Schwab, U. M. Zanger, C. Marx et al. , "Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group," Journal of Clinical Oncology, vol. 26, no. 13, pp. 2131-2138, 2008.
9. M. H. Kristensen, P. L. Pedersen, G. V. Melsen, J. Ellehauge, and J. Mejer, "Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients," Journal of International Medical Research, vol. 38, no. 3, pp. 870-883, 2010.
10. R. R. Kaldate, A. Haregewoin, C. E. Grier, S. A. Hamilton, and H. L. McLeod, "Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6," Oncologist, vol. 17, no. 3, pp. 296-302, 2012.
11. L. K. Teh, S. Hamzah, H. Hashim et al. , "Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5- fluorouracil therapy among colorectal cancer patients," Therapeutic Drug Monitoring, vol. 35, no. 5, pp. 624-630, 2013.
12. J. Ciccolini, E. Gross, L. Dahan, B. Lacarelle, and C. Mercier, "Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?" Clinical Colorectal Cancer, vol. 9, no. 4, pp. 224-228, 2010.
13. M. J. Deenen, J. Tol, A. M. Burylo et al. , "Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer," Clinical Cancer Research, vol. 17, no. 10, pp. 3455-3468, 2011.
14. E. Gross, B. Busse, M. Riemenschneider et al. , "Strong association of a common dihydopyramidine dehydrogenase gene polymorphism with flouropyrimidine-related toxicity in cancer patients," PLoS ONE, vol. 3, no. 12, Article IDe4003, 2008.
15. X. Wei, G. Elizondo, A. Sapone et al. , "Characterization of the human dihydropyrimidine dehydrogenase gene," Genomics, vol. 51, no. 3, pp. 391-400, 1998.
16. U. Amstutz, T. K. Froehlich, and C. R. Largiadr, "Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5- fluorouracil toxicity," Pharmacogenomics, vol. 12, no. 9, pp. 1321- 1336, 2011.
17. X. Zhang, B.-T. Sun, and Z.-X. Lu, "Relationship between SNP of DPYD and 5-fluorouracil toxicity in colorectal cancer patients," Journal of Jilin University, vol. 37, no. 4, pp. 707-711, 2011.
18. X. Cai, J. M. Fang, P. Xue et al. , "IVS14+1G>A Ggt;A genotype in the dihydropyrimidine dehydrogenase gene: a predictive marker with fluorouracil pharmacokinetic in reducing adverse reactions of fluorouracil-based chemotherapy in patients with local advanced and metastatic colorectal cancer," China Oncology, vol. 23, no. 2, pp. 130-136, 2013.
19. A. Stang, "Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmetaanalyses," European Journal of Epidemiology, vol. 25, no. 9, pp. 603-605, 2010.
20. E. Zintzaras and J. P. A. Ioannidis, "HEGESMA: genome search meta-analysis and heterogeneity testing," Bioinformatics, vol. 21, no. 18, pp. 3672-3673, 2005.
21. J. L. Peters, A. J. Sutton, D. R. Jones, K. R. Abrams, and L. Rushton, "Comparison of twomethods to detect publication bias in meta-analysis," Journal of theAmericanMedical Association, vol. 295, no. 6, pp. 676-680, 2006.
22. H. Zhang, Y.-M. Li, and X. Jin, "DPYD?5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients," Medical Oncology, vol. 24, no. 2, pp. 251-258, 2007.
23. M. Raida, W. Schwabe, P. Häusler et al. , "Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls," Clinical Cancer Research, vol. 7, no. 9, pp. 2832-2839, 2001.